Результати пошуку - Timothy Devos

Уточнити результати
  1. 1
    CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis

    CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis за авторством Gaël Vermeersch, Paul Proost, Sofie Struyf, Mieke Gouwy, Timothy Devos

    Опубліковано 2024
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  2. 2
    Machine perfusion in organ transplantation

    Machine perfusion in organ transplantation за авторством Dirk Van Raemdonck, Arne Neyrinck, Filip Rega, Timothy Devos, Jacques Pirenne

    Опубліковано 2012
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  3. 3
    Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel

    Diagnosis and management of PNH: Review and recommendations from a Belgian expert panel за авторством Timothy Devos, Stef Meers, Nancy Boeckx, André Gothot, Dries Deeren, Bernard Châtelain, C Chatelain, Bérangère Devalet

    Опубліковано 2018
    Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:
  4. 4
    Myeloablative Conditioning Predisposes Patients for<i>Toxoplasma gondii</i>Reactivation after Allogeneic Stem Cell Transplantation

    Myeloablative Conditioning Predisposes Patients for<i>Toxoplasma gondii</i>Reactivation after Allogeneic Stem Cell Transplantation за авторством Stef Meers, Katrien Lagrou, Koen Theunissen, Daan Dierickx, Michel Delforge, Timothy Devos, Ann Janssens, Wouter Meersseman, Gregor Verhoef, Johan Van Eldere, Johan Maertens

    Опубліковано 2010
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  5. 5
    Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study

    Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study за авторством Francesco Passamonti, Francesca Palandri, Güray Saydam, Jeannie Callum, Timothy Devos, Paola Guglielmelli, Alessandro M. Vannucchi, Evren Zor, Mike W. Zuurman, Geralyn Gilotti, Yifan Zhang, Martin Grießhammer

    Опубліковано 2022
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  6. 6
    Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Phase 1 Trial

    Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transpl... за авторством Richard T. Maziarz, Timothy Devos, Carlos Bachier, Steven C. Goldstein, José F. Leis, Steven M. Devine, Gabrielle Meyers, James Gajewski, Johan Maertens, Robert Deans, Wouter van’t Hof, Hillard M. Lazarus

    Опубліковано 2014
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  7. 7
    Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

    Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial за авторством Martin Grießhammer, Güray Saydam, Francesca Palandri, Giulia Benevolo, Miklós Egyed, Jeannie Callum, Timothy Devos, Serdar Şıvgın, Paola Guglielmelli, Caroline Bensasson, Md Mahmudul Hasan Khan, Julian Perez Ronco, Francesco Passamonti

    Опубліковано 2018
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  8. 8
    Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations

    Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations за авторством Carla Al Assaf, Florence Van Obbergh, Johan Billiet, Els Lierman, Timothy Devos, Carlos Graux, Anne-Sophie Hervent, Jan Emmerechts, Thomas Tousseyn, Pascale De Paepe, Petros Papadopoulos, Lucienne Michaux, Peter Vandenberghe

    Опубліковано 2015
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  9. 9
    SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis

    SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis за авторством Ruben A. Mesa, Jean‐Jacques Kiladjian, John Catalano, Timothy Devos, Miklós Egyed, Andrzei Hellmann, Donal P. McLornan, Kazuya Shimoda, Elliott F. Winton, Wei Deng, Ronald L. Dubowy, Julia D. Maltzman, Francisco Cervantes, Jason Gotlib

    Опубліковано 2017
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  10. 10
    A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence

    A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence за авторством Ayalew Tefferi, Haifa Kathrin Al‐Ali, Giovanni Barosi, Timothy Devos, Heinz Gisslinger, Qingwu Jiang, Jean‐Jacques Kiladjian, Ruben A. Mesa, Francesco Passamonti, Vincent Ribrag, Gary J. Schiller, Alessandro M. Vannucchi, D Zhou, D Reiser, Judy Zhong, Gale Rp

    Опубліковано 2016
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  11. 11
    Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies

    Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack... за авторством Albrecht Betrains, Laurent Godinas, F. J. Sherida H. Woei‐A‐Jin, Wouter Rosseels, Yannick Van Herck, Natalie Lorent, Daan Dierickx, Veerle Compernolle, Geert Meyfroidt, Lore Vanderbeke, Valentijn Vergote, Katrien Lagrou, Peter Verhamme, Joost Wauters, Pieter Vermeersch, Timothy Devos, Piet Maes, Steven Vanderschueren

    Опубліковано 2020
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  12. 12
    Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis

    Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis за авторством Ruben A. Mesa, Claire Harrison, Stephen T. Oh, Aaron T. Gerds, Vikas Gupta, John Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean‐Jacques Kiladjian, Ewa Lech‐Marańda, Donal P. McLornan, Alessandro M. Vannucchi, Uwe Platzbecker, Mei Huang, Bryan Strouse, Barbara Klencke, Srđan Verstovšek

    Опубліковано 2022
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  13. 13
    Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis

    Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis за авторством Stephen T. Oh, Srđan Verstovšek, Vikas Gupta, Uwe Platzbecker, Timothy Devos, Jean‐Jacques Kiladjian, Donal P. McLornan, Andrew C. Perkins, María Laura Fox, Mary Frances McMullin, Adam J. Mead, Miklós Egyed, Jiří Mayer, Tomasz Sacha, Jun Kawashima, Mei Huang, Bryan Strouse, Ruben A. Mesa

    Опубліковано 2024
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  14. 14
    KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia

    KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia за авторством Roel Willemze, Celso Arrais‐Rodrigues, Myriam Labopin, Guillermo Sanz, Gérard Michel, Gèrard Socié, Bernard Rio, Anne Sîrvent, M. Renaud, Luís Madero, Mohamad Mohty, Christelle Ferrà, Federico Garnier, Philippe M. Loiseau, Juan Carlos García‐Ruiz, Lucilla Lecchi, G. Kögler, Yves Béguin, Cristina Navarrete, Timothy Devos, Irina Ionescu, Karim Boudjedir, A-L Herr, Éliane Gluckman, Vanderson Rocha

    Опубліковано 2009
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  15. 15
    A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

    A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis за авторством Francesco Passamonti, Toni Giorgino, Barbara Mora, Paola Guglielmelli, Elisa Rumi, Margherita Maffioli, Alessandro Rambaldi, Marianna Caramella, Rami S. Komrokji, Jason Gotlib, Jean‐Jacques Kiladjian, Francisco Cervantes, Timothy Devos, Francesca Palandri, Valerio De Stefano, Marco Ruggeri, Richard T. Silver, Giulia Benevolo, Francesco Albano, Domenica Caramazza, Michele Merli, Daniela Pietra, Rosario Casalone, Giada Rotunno, Tiziano Barbui, Mario Cazzola, Alessandro M. Vannucchi

    Опубліковано 2017
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  16. 16
    Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma

    Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma за авторством Timothy Devos, Quentin Van Thillo, Veerle Compernolle, Tomé Najdovski, Márta Romano, Nicolás Dauby, Laurent Jadot, Mathias Leys, Evelyne Maillart, Sarah Loof, Lucie Seyler, Martial Moonen, Michel Moutschen, Niels Van Regenmortel, Kevin K. Ariën, Cyril Barbezange, Albrecht Betrains, Mutien‐Marie Garigliany, Matthias M. Engelen, Iwein Gyselinck, Piet Maes, Alexander Schauwvlieghe, Laurens Liesenborghs, Ann Belmans, Peter Verhamme, Geert Meyfroidt

    Опубліковано 2021
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  17. 17
    MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis

    MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis за авторством John Mascarenhas, Marina Kremyanskaya, Andrea Patriarca, Francesca Palandri, Timothy Devos, Francesco Passamonti, Raajit K. Rampal, Adam J. Mead, Gabriella Hobbs, Joseph M. Scandura, Moshe Talpaz, Nikki Granacher, Tim C. P. Somervaille, Ronald Hoffman, Mariëlle J. Wondergem, Mohamed E. Salama, Gozde Colak, Jike Cui, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Srđan Verstovšek, Natalia Curto‐García, Claire Harrison, Vikas Gupta

    Опубліковано 2023
    Отримати повний текст Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  18. 18
    Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

    Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo... за авторством Naveen Pemmaraju, Adam J. Mead, Tim C. P. Somervaille, James McCloskey, Francesca Palandri, Steffen Koschmieder, David Lavie, Brian Leber, Su‐Peng Yeh, María Teresa Gómez‐Casares, Emanuele Ammatuna, Ho‐Jin Shin, Keita Kirito, Éric Jourdan, Timothy Devos, Hun Chuah, Atanas Radinoff, Andrija Bogdanović, Rastislav Moskal, Qi Jiang, Avijeet Chopra, Elektra J. Papadopoulos, Jalaja Potluri, Francesco Passamonti

    Опубліковано 2023
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  19. 19
    Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis

    Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis за авторством Claire Harrison, Vikas Gupta, Aaron T. Gerds, Raajit K. Rampal, Srđan Verstovšek, Moshe Talpaz, Jean‐Jacques Kiladjian, Ruben A. Mesa, Andrew Kuykendall, Alessandro M. Vannucchi, Francesca Palandri, Sebastian Grosicki, Timothy Devos, Éric Jourdan, Mariëlle J. Wondergem, Haifa Kathrin Al‐Ali, Veronika Buxhofer‐Ausch, Alberto Álvarez‐Larrán, Andrea Patriarca, Marina Kremyanskaya, Adam J. Mead, Sanjay Akhani, Yuri Sheikine, Gozde Colak, John Mascarenhas

    Опубліковано 2022
    Отримати повний текст
    Artigo
    Додати у Вибране
    Збережено в:
  20. 20
    Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19

    Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19 за авторством Andrea B. Troxel, Eva Petkova, Keith Goldfeld, Mengling Liu, Thaddeus Tarpey, Yinxiang Wu, Danni Wu, Anup Agarwal, C. Avendaño, Emma Bainbridge, Katherine J. Bar, Timothy Devos, Rafael F. Duarte, Arvind Gharbharan, Priscilla Y. Hsue, Deepak Kumar, Annie Luetkemeyer, Geert Meyfroidt, André Moraes Nicola, Aparna Mukherjee, Mila B. Ortigoza, Liise-anne Pirofski, Bart Rijnders, Casper Rokx, Arantxa Sancho-López, Pamela A. Shaw, Pablo Tebas, Hyunah Yoon, Corita R. Grudzen, Judith S. Hochman, Elliott M. Antman

    Опубліковано 2022
    Отримати повний текст Отримати повний текст
    Revisão
    Додати у Вибране
    Збережено в:

Інструменти для пошуку: